We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
05 Nov 2020 - 07 Nov 2020

Antibody Detection Is Critical for COVID-19 Diagnosis

By LabMedica International staff writers
Posted on 06 May 2020
Print article
Image: Antibody Detection Is Critical for COVID-19 Diagnosis (Photo courtesy of Minnesota Department of Health).
Image: Antibody Detection Is Critical for COVID-19 Diagnosis (Photo courtesy of Minnesota Department of Health).
Accurate and fast diagnosis of the causative SARS CoV-2 is important to isolate the patients with COVID-19 timely and stop the epidemics, as well as save people's lives. Viral nucleic acid detection using real-time polymerase chain reaction (RT-PCR) assay, which has been developed and used for detection of SARS-CoV-2 rapidly, remains the standard diagnosis of COVID-19.

The human antibody response which is crucial for the clearance of the initial virus infection has been widely used to help diagnosis virus infection. Compared to RT-PCR assays, the detection of antibody assays are often faster, less expensive, easy-to-use and accessible to staff without laboratory training. The antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be detected in the middle and later stage of the illness using an enzyme-linked immunosorbent assay.

Scientists at the Tongji Medical College (Wuhan, China) evaluated IgM and IgG antibody responses to SARS-CoV-2 virus infection from patients treated at Union Hospital between January 19, 2020, and March 2, 2020. A total of 216 serum samples from 85 patients with confirmed coronavirus disease 2019 (COVID-19) were obtained in different time periods after symptoms onset.

Total RNAs were extracted from nasopharyngeal and/or oropharyngeal swabs samples of patients suspected of having SARS-CoV-2 infection within two hours using the respiratory sample RNA isolation kit and were used for real-time RT-PCR assay of SARS-CoV-2 RNA. The serum SARS-CoV-2 antibodies (IgM and IgG) of the subjects were detected using a sandwich enzyme linked immunosorbent assay (Livzon Inc, Zhuhai, China).

The scientists reported that the IgM and IgG antibodies were detected positive as early as on the 4th day after onset. The seropositive rate of IgM increased gradually and IgG was increased sharply on the 12th day after onset. In the confirmed patients with COVID-19, the sensitivity rate of IgM was 77.3%, specificity was 100%, positive predictive value (PPV) was 100%, negative predictive value (NPV) was 80%, and consistency rate was 88.1%. The respective rates for IgG were 83.3.3%, 95.0%, 94.8%, 83.8%, and 88.9%. In a different cohort of 24 patients with suspected COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 87.5%, 100%, 100%, 95.2%, and 96.4%. The respective rates for IgG were 70.8%, 96.6%, 85.0%, 89.1%, and 88.1%.

The authors concluded that the detection of antibodies against COVID-19 based on ELISA appears to be a valid approach to serodiagnosis of COVID-19 pneumonia. The specific circulating antibody can be uniformly detected, therefore avoiding false-negative results due to sampling or potential absence of viruses in the respiratory system. COVID-19 pneumonia can be diagnosed based on seropositive of specific antibodies as an alternative to viral nucleic acid detection with clear advantages. The study was published on April 19, 2020 in the journal Clinical Infectious Diseases.

Related Links:
Tongji Medical College
Livzon Inc

Print article
BIOHIT  Healthcare OY


Industry News

view channel
Image: Randox and Bosch Healthcare Collaboratively Combat COVID-19 with Game-Changing Partnership (Photo courtesy of Randox Laboratories)

Randox and Bosch Healthcare Collaboratively Combat COVID-19 with Game-Changing Partnership

The game-changing partnership between Randox Laboratories (Crumlin, UK) and Bosch Healthcare (Waiblingen, Germany) continues to alter the testing landscape and capabilities of both laboratory and non-laboratory... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.